Addressing
the Challenges
of Alzheimer’s Agitation
Targeting Agitation in Alzheimer's Disease IGC-AD1 has completed enrollment in the Phase 2 CALMA trial. Topline results expected Q4 2026.
Our Science,
Our Commitment
IGC Pharma is a clinical-stage biotechnology company dedicated to advancing Alzheimer’s research through scientific rigor, technological innovation, and a strong commitment to patients and caregivers.
CALMA
CALMA is a multicenter Phase 2 trial evaluating the safety and efficacy of IGC-AD1 for agitation in patients with dementia due to Alzheimer's disease. Enrollment is complete, and topline results are expected in Q4 2026.
IGC-AD1
IGC-AD1 is IGC Pharma’s lead candidate—a partial CB1 receptor agonist with anti-inflammatory action, designed to address agitation associated with Alzheimer’s disease.
Artificial Intelligence
Our AI transforms multimodal data into actionable insights, empowering physicians with early Alzheimer’s prediction and more precise clinical decision support.
Latest Press Releases
Explore how IGC Pharma’s data, trials, and milestones are shaping a brighter future for Alzheimer’s care.
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer’s Trial Moves Within Six Randomizations of Enrollment Closure
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topline Readout
Together, we’re turning research into resilience, and innovation into care for millions of families.
People age 65 and older live with Alzheimer's disease today in the U.S.1
People are projected to have Alzheimer's disease by 2060 in the U.S.1
Leading cause of death among all ages in the United States1.
Expected cost of Alzheimer’s and dementia by 2050 (in 2025 dollars) if no treatment or cure is available1.
Pipeline
IGC Pharma’s pipeline bridges breakthroughs from AI-enhanced
early detection to IGC-AD1 and beyond, advancing Alzheimer’s
treatment frontiers.
In-depth insights,
real impact
Science Spotlight covers the research, breakthroughs, and shaping Alzheimer's today.
Resources
for Caregivers
A compassionate, evidence-based guide for families caring for someone with Alzheimer's. Written by leading neuropsychologists and built around real caregiver stories, it offers practical strategies for daily challenges — and for protecting your own well-being. Free, from IGC Pharma.
Investing in the Future
IGC Pharma stands with families and vulnerable groups, investing in research, education, advocacy and Alzheimer’s awareness.
- 2025 Alzheimer’s disease facts and figures. Alzheimers Dement. 2025;21(4):e70235. Published 2025 Apr 29. doi:10.1002/alz.70235